The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects

Cancer Investigation
J C BerghB I Nilsson

Abstract

Roquinimex (Linomide) has been demonstrated to suppress tumor growth in animal models. The effect is at least in part related to enhanced numbers and activity of natural killer (NK) cells. In this clinical pilot study, roquinimex was given at increasing doses (0.05 mg/kg to 0.6 mg/kg) to 13 patients (performance status 0-3) with various malignant disorders. Immunology parameters were followed and side effects were observed during the study. The plasma pharmacokinetics of roquinimex was studied at the 0.2 mg/kg dose level. The clinical side effects were dominated by musculoskeletal discomfort, nausea, and pain. No significant hematological or biochemical toxicity was observed. Pharmacokinetic analysis at the 0.2 mg/kg dose level revealed a Cmax of 4.0 mumol/L at tmax of 1.2 hr and an elimination half-life of 42 hr. Increased numbers of phenotypic NK cells, activated T (DR+CD4+) cells, and monocytes were observed after administration of roquinimex compared with pretreatment values. Roquinimex seems to be an active immunomodulator with manageable toxicity. Further exploration of therapeutic efficacy is warranted.

References

Jan 1, 1989·Drug Metabolism Reviews·T F Woolf, L L Radulovic
Jan 1, 1989·Current Opinion in Immunology·A Mantovani
Jan 1, 1989·Current Opinion in Immunology·J J Killion, I J Fidler
Jan 1, 1987·International Journal of Immunopharmacology·E L LarssonT Stålhandske
Nov 1, 1986·Arthritis and Rheumatism·A TarkowskiT Stålhandske

❮ Previous
Next ❯

Citations

Nov 15, 2002·Molecular and Cellular Endocrinology·R J A van Moorselaar, E E Voest
Dec 22, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·M ShalevI Gery
Apr 13, 2000·Biopharmaceutics & Drug Disposition·K StrandgârdenP O Gunnarsson
Jun 13, 2000·Bone Marrow Transplantation·B SimonssonB I Nilsson
Nov 11, 1999·Medizinische Klinik·D SchieferA Engert
Aug 9, 2019·Acta Crystallographica. Section E, Crystallographic Communications·Younos BouzianEl Mokhtar Essassi
Dec 13, 2005·Journal of Medicinal Chemistry·Raveendra DayamNouri Neamati

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.